Cellceutix Corp. presented a poster yesterday at the American Association for Cancer Research (AACR) 101st Annual Meeting in Washington, D.C. on their lead drug, Kevetrin™. The poster was titled “Novel Small Molecule has Potent Anti-tumor Activity in Drug Resistant Human Carcinoma Xenograft Models.”

Cellceutix is developing Kevetrin for treatment of specific cancer cell lines that are proven to be resistant to standard anti-cancer treatments. The poster presented new data that had not yet been released to the public regarding further research on Kevetrin as it approaches human trials. The data from the research showed two significant results in the mouse model regarding lung cancer cell lines.

1. Data showed that the efficacy of Kevetrin in a mouse model of drug resistant lung cancer increases with increasing dose.
2. Data showed that the administration of a second cycle of therapy with Kevetrin in the same animal model continues to delay tumor growth without the development of resistance.

In addition to this data that has been added to a growing list of positive results in early studies of Kevetrin on lung cancer, more data has been accumulated showing a positive effect for Kevetrin in animal models of drug-resistant colon and breast cancer cell lines. This data was also included in the poster.

George Evans, CEO of Cellceutix, was quoted in the latest Cellceutix press release as stating, “We are extremely pleased to be able to present these important new data at AACR,” He went on to say, “These data again show strong activity in a resistant lung cancer cell line and the fact that Kevetrin delays tumor growth in a dose dependent manner is important as we move toward a phase 1 human trial.”

Cellceutix Corporation, a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, completed a pre-IND (Investigational New Drug) meeting with the United States Food and Drug Administration (FDA) for Kevetrin in February and is working towards finalizing all pre-IND studies required by the FDA. Cellceutix had also presented a poster on Kevetrin in October of 2009 in which the AACR featured the Cellceutix research on the abstract.